JPWO2019140324A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019140324A5 JPWO2019140324A5 JP2020535980A JP2020535980A JPWO2019140324A5 JP WO2019140324 A5 JPWO2019140324 A5 JP WO2019140324A5 JP 2020535980 A JP2020535980 A JP 2020535980A JP 2020535980 A JP2020535980 A JP 2020535980A JP WO2019140324 A5 JPWO2019140324 A5 JP WO2019140324A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- combination
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 108090001123 antibodies Proteins 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 229910052805 deuterium Inorganic materials 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 2
- 201000005216 brain cancer Diseases 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 229950002916 Avelumab Drugs 0.000 claims 1
- 108010090685 BMS-936559 Proteins 0.000 claims 1
- 102100007290 CD274 Human genes 0.000 claims 1
- 101710012053 CD274 Proteins 0.000 claims 1
- 229950009791 Durvalumab Drugs 0.000 claims 1
- 108010019706 Nivolumab Proteins 0.000 claims 1
- 229950010773 Pidilizumab Drugs 0.000 claims 1
- 108010072668 atezolizumab Proteins 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 108010010826 avelumab Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010016436 durvalumab Proteins 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 108010026276 pembrolizumab Proteins 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 108010051812 pidilizumab Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862616729P | 2018-01-12 | 2018-01-12 | |
| US62/616,729 | 2018-01-12 | ||
| PCT/US2019/013377 WO2019140324A1 (en) | 2018-01-12 | 2019-01-11 | Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021510680A JP2021510680A (ja) | 2021-04-30 |
| JPWO2019140324A5 true JPWO2019140324A5 (de) | 2022-02-07 |
Family
ID=67212721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535980A Pending JP2021510680A (ja) | 2018-01-12 | 2019-01-11 | Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10435434B2 (de) |
| EP (1) | EP3713571A4 (de) |
| JP (1) | JP2021510680A (de) |
| KR (1) | KR20200119246A (de) |
| CN (1) | CN111886010A (de) |
| AU (1) | AU2019206652A1 (de) |
| CA (1) | CA3087009A1 (de) |
| EA (1) | EA202091630A1 (de) |
| MX (1) | MX2020007293A (de) |
| WO (1) | WO2019140324A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3331542A4 (de) | 2015-08-03 | 2019-04-03 | ENB Therapeutics, LLC | Zusammensetzungen und verfahren zur behandlung von mit etbr-aktivierung assoziiertem krebs |
| CA3087009A1 (en) | 2018-01-12 | 2019-07-18 | Enb Therapeutics, Inc. | Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation |
| TW202120486A (zh) * | 2019-08-09 | 2021-06-01 | 英商阿帝歐斯製藥有限公司 | 新穎化合物 |
| WO2024092239A1 (en) * | 2022-10-28 | 2024-05-02 | Enb Therapeutics, Inc. | Methods for treating cancers associated with etbr activation |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4874780A (en) * | 1987-03-11 | 1989-10-17 | Norsk Hydro A.S. | Anticancer compounds |
| ATE423130T1 (de) * | 1997-10-08 | 2009-03-15 | Isotechnika Inc | Deuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agenzien |
| US7566452B1 (en) * | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| WO2004037235A2 (en) | 2002-10-24 | 2004-05-06 | The Board Of Trustees Of The University Of Illinois | Method and composition for preventing and treating solid tumors |
| US7713440B2 (en) | 2003-10-08 | 2010-05-11 | Lyotropic Therapeutics, Inc. | Stabilized uncoated particles of reversed liquid crystalline phase materials |
| WO2006019637A2 (en) | 2004-07-07 | 2006-02-23 | The Regents Of The University | An intelligent nanomedicine integrating diagnosis and therapy |
| US20080102451A1 (en) | 2006-10-31 | 2008-05-01 | Abbott Laboratories | Companion diagnostic assays for endothelin receptor antagonists |
| US8071596B2 (en) * | 2007-01-12 | 2011-12-06 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| US9289426B2 (en) | 2007-03-21 | 2016-03-22 | University Of Pennsylvania | Methods and compositions for treating solid tumors and enhancing tumor vaccines |
| CN101873858B (zh) | 2007-06-11 | 2016-05-25 | R·骆克·麦克唐纳 | 用于预防脑血管痉挛的药物递送系统 |
| AU2009286247A1 (en) | 2008-08-29 | 2010-03-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Delivery of a CD40 agonist to a tumor draining lymph node of a subject |
| US20110053968A1 (en) * | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
| DK2464218T3 (en) | 2009-08-10 | 2015-07-20 | Univ Texas | Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic agent for chemotherapy |
| US20140341916A1 (en) | 2011-10-28 | 2014-11-20 | Genentech, Inc. | Therapeutic combinations and methods of treating melanoma |
| TWI613215B (zh) | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途 |
| US10233277B2 (en) | 2012-03-02 | 2019-03-19 | The Governing Council Of The University Of Toronto | Polymeric nanoparticles useful in theranostics |
| WO2014025837A1 (en) | 2012-08-06 | 2014-02-13 | Board Of Regents, The University Of Texas System | Methods for treatment and prevention of tauopathies by inhibiting endothelin receptors |
| CN112353943A (zh) | 2013-12-17 | 2021-02-12 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法 |
| EP3527587A1 (de) | 2013-12-17 | 2019-08-21 | F. Hoffmann-La Roche AG | Kombinationstherapie mit ox40-bindungsagonisten und pd-l1-bindungsantagonisten |
| WO2015110593A1 (en) * | 2014-01-24 | 2015-07-30 | Cecilia Naucler | Use of endothelial receptor b inhibitors in prevention and treatment of human cytomegalovirus infection and cmv-related pathologies such as cardiovascular diseases and cancer |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| HRP20201900T4 (hr) | 2015-05-12 | 2024-06-07 | F. Hoffmann - La Roche Ag | Terapeutski i dijagnostički postupci kod raka |
| WO2016196298A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Therapeutic and diagnolstic methods for cancer |
| JP6884111B2 (ja) | 2015-05-29 | 2021-06-09 | ジェネンテック， インコーポレイテッド | 癌におけるｐｄ−ｌ１プロモーターのメチル化 |
| EP3331542A4 (de) * | 2015-08-03 | 2019-04-03 | ENB Therapeutics, LLC | Zusammensetzungen und verfahren zur behandlung von mit etbr-aktivierung assoziiertem krebs |
| MX2018010361A (es) | 2016-02-29 | 2019-07-08 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
| WO2017165491A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
| CA3087009A1 (en) | 2018-01-12 | 2019-07-18 | Enb Therapeutics, Inc. | Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation |
| EP3746110A4 (de) | 2018-03-30 | 2022-03-02 | ENB Therapeutics, Inc. | Etbr-antagonist-verbindungen, zusammensetzungen und verwendungen |
| US20220265628A1 (en) | 2019-07-17 | 2022-08-25 | Enb Therapeutics, Inc. | Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists |
| US20200289495A1 (en) | 2020-03-24 | 2020-09-17 | Enb Therapeutics, Inc. | Methods of inhibiting endothelin b receptor expressing tumor metastases |
| US20200268829A1 (en) | 2020-03-24 | 2020-08-27 | Enb Therapeutics, Inc. | Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer |
-
2019
- 2019-01-11 CA CA3087009A patent/CA3087009A1/en active Pending
- 2019-01-11 WO PCT/US2019/013377 patent/WO2019140324A1/en unknown
- 2019-01-11 US US16/246,398 patent/US10435434B2/en active Active
- 2019-01-11 KR KR1020207022798A patent/KR20200119246A/ko not_active Application Discontinuation
- 2019-01-11 EP EP19738888.7A patent/EP3713571A4/de active Pending
- 2019-01-11 CN CN201980018691.9A patent/CN111886010A/zh active Pending
- 2019-01-11 MX MX2020007293A patent/MX2020007293A/es unknown
- 2019-01-11 AU AU2019206652A patent/AU2019206652A1/en active Pending
- 2019-01-11 JP JP2020535980A patent/JP2021510680A/ja active Pending
- 2019-01-11 EA EA202091630A patent/EA202091630A1/ru unknown
- 2019-07-30 US US16/526,862 patent/US11066442B2/en active Active
-
2021
- 2021-06-17 US US17/350,497 patent/US20210309694A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535746A5 (de) | ||
| JP2019535744A5 (de) | ||
| JP2018500342A5 (de) | ||
| JP2020517616A5 (de) | ||
| JP2020506951A5 (de) | ||
| JP2019511565A5 (de) | ||
| JP2018516243A5 (de) | ||
| JP2014524441A5 (de) | ||
| JP2018508572A5 (de) | ||
| JP2018511628A5 (de) | ||
| JP2007511504A5 (de) | ||
| JP2020500182A5 (de) | ||
| TW202028212A (zh) | Ｓｔｉｎｇ促效化合物 | |
| RU2006139258A (ru) | Бензотриазиновые ингибиторы киназ | |
| JP2007517044A5 (de) | ||
| JP2018502902A5 (de) | ||
| TW505636B (en) | Polar-substituted hydrocarbons | |
| JP2013503139A5 (de) | ||
| RU2012149448A (ru) | Новые конъюгаты аналогов сс-1065 и бифункциональные линкеры | |
| JP2006515858A5 (de) | ||
| JP2022515273A (ja) | Ｆａｋ阻害剤およびその併用薬物 | |
| RU2007116987A (ru) | Новые соединения | |
| JP2011526917A5 (de) | ||
| JP2006517201A5 (de) | ||
| JPWO2019148150A5 (de) |